Last update 01 Nov 2024

EGFR x VEGFR2 x CD20 x CD19

Basic Info

Related Targets
EGFRVEGFR2CD20[+1]

Related

1
Drugs associated with EGFR x VEGFR2 x CD20 x CD19
Diakine-DK210
Target
CD19 x CD20 x EGFR x VEGFR2
Mechanism
CD19 inhibitors [+3]
Active Org.
Deka Biosciences, Inc.
Originator Org.
Deka Biosciences, Inc.
Active Indication
Colorectal Cancer [+6]
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
1
Clinical Trials associated with EGFR x VEGFR2 x CD20 x CD19
NCT05704985 / RecruitingPhase 1
Dose-finding Phase 1 Trial: Evaluating Safety and Biomarkers Using DK210 (EGFR) for Inoperable Locally Advanced and/or Metastatic EGFR+ Tumors With Progressive Disease Failing Systemic Therapy
100 Clinical Results associated with EGFR x VEGFR2 x CD20 x CD19
Login to view more data
100 Translational Medicine associated with EGFR x VEGFR2 x CD20 x CD19
Login to view more data
0 Patents (Medical) associated with EGFR x VEGFR2 x CD20 x CD19
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free